CoChat

The DOI matches its Crossref record; 138 of the 144 references it cites were found in a registry or an index; 96 of the 238 sources its claims cite were checked for support.

The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

Open access
Biondi, Bernadette, Bartalena, Luigi, Cooper, David S., Hegedüs, Laszlo, Laurberg, Peter, Kahaly, George J. · 2015 · European Thyroid Journal

Abstract

Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.

Overview

CoChat Summary

TL;DR

The 2015 European Thyroid Association guidelines define endogenous subclinical hyperthyroidism (SHyper) biochemically as a persistently subnormal serum TSH with normal free thyroxine and triiodothyronine levels, divided into grade 1 (TSH 0.1–0.39 mIU/l) and grade 2 (TSH <0.1 mIU/l). They recommend treating older patients with grade 2 SHyper, considering treatment in older patients with grade 1 SHyper and younger symptomatic patients with grade 2 SHyper, and not treating younger asymptomatic patients with grade 1 SHyper.

Key findings

  • SHyper prevalence varies widely, from 0.6 to 16%; in NHANES it was 0.7% with a TSH cutoff <0.1 mIU/l and 1.8% with a cutoff <0.4 mIU/l, and it can be as high as 15% in iodine-deficient subjects >70 years.
  • Grade 2 SHyper carries higher risks than grade 1: progression to overt hyperthyroidism was 5–8% per year in grade 2 versus 0.5–0.7% over 7 years in grade 1, and one retrospective study reported progression in 20% of grade 2 versus 6.8% of grade 1 patients over 7 years (p < 0.001).
  • Meta-analyses showed increased risks with SHyper, especially grade 2: incident atrial fibrillation HR 2.54 (95% CI 1.08–5.99) for grade 2 and 1.63 (95% CI 1.10–2.41) for grade 1; heart failure HR 1.94 (95% CI 1.01–3.72) for grade 2 and 1.31 (95% CI 0.88–1.95) for grade 1; total mortality HR 1.24 (95% CI 1.06–1.46); CHD mortality HR 1.84 (95% CI 1.12–3.00) for grade 2; fracture HRs were 1.52 (95% CI 1.19–1.93) for hip fracture, 1.42 (95% CI 1.16–1.74) for any fracture, and 1.74 (95% CI 1.01–2.99) for spine fracture.
  • Treatment recommendations: treat patients >65 years with grade 2 SHyper (1/++0); consider treatment in patients >65 years with grade 1 SHyper (2/+00); suggest treating patients <65 years with persistent and/or symptomatic grade 2 SHyper (2/+00); and do not recommend treating young asymptomatic patients with grade 1 SHyper (2/+00). ATDs are first choice in young patients with Graves’ disease and grade 2 SHyper and in patients >65 years with Graves’ disease and grade 1 SHyper; RAI or surgery is preferred for older patients with toxic multinodular goitre or toxic adenoma.

Methods

  • An ETA task force was formed in 2014 and performed a systematic literature review searching Medline for “subclinical hyperthyroidism” from May 1974 to July 2015, restricted to English-language reports but including translated articles, plus personal files and references.
  • The task force used the GRADE system, rating recommendation strength as 1 (strong) or 2 (weak) and evidence quality as +++ (high, level A), ++0 (moderate, level B), or +00 (low, level C); because few randomized controlled trials were available, nonrandomized trials and expert opinions were also considered.
  • Draft recommendations were posted on the ETA members-only website for 4 weeks, comments were incorporated, and the final document was approved by the ETA Guidelines Board and Executive Committee.

Limitations

  • The paper states that there are no randomized prospective trials demonstrating that treatment of SHyper improves the associated cardiovascular and skeletal risks, and that two European trials were terminated because they did not complete recruitment.
  • The paper states that in most prospective studies thyroid function was measured only at baseline, FT3 was measured in only a few cohorts, and the aetiology of hyperthyroidism was not considered.
  • Evident from the text: many recommendations rely on observational cohort studies, meta-analyses of individual participant data, and expert opinion, with several recommendations graded weak (2) and/or supported by low-quality evidence (+00); treatment benefit itself remains unproven in randomized trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1159/000438750

Cites

138 of 139 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

70 Valid · 4 Not valid · 86 Not checked · 11 Own results and interpretations

123 more claims · 55 with their cited sources checked

Create a free account to see all 171 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 139 references

Cited by

See all 323

Metadata

Authors
Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J.
Affiliations
  • Federico II University Hospital (IT)
  • University of Insubria (IT)
  • Johns Hopkins University (US)
  • 4Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
  • Aalborg University Hospital (DK)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
Venue
European Thyroid Journal
Published
2015-08-26
Volume
4
Issue
3
Pages
149-163
ISSN
  • 2235-0640 (ISSN-L)
  • 2235-0802
OpenAlex
W1562308323
Cited by
323
References
144
Citations by year
2026: 18 · 2025: 26 · 2024: 34 · 2023: 27 · 2022: 32 · 2021: 39 · 2020: 40 · 2019: 16 · 2018: 38 · 2017: 30 · 2016: 20 · 2015: 3
FWCI
26.30
Type
journal article
Language
en
Open access
Locations
  • European Thyroid Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, other-oa)
  • IrInSubria (University of Insubria) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords
subclinical hyperthyroidism, Graves' disease, autonomously functioning thyroid nodules, multinodular goiter, thyroid-stimulating hormone, cardiovascular risk, atrial fibrillation, heart failure, fracture, elderly patients, treatment indications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. https://app.cochat.ai/papers/10.1159/000438750
The paper
Biondi, B., Bartalena, L., Cooper, D. S., Hegedüs, L., Laurberg, P., & Kahaly, G. J. (2015). The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. European Thyroid Journal. https://doi.org/10.1159/000438750

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.